Increased Photosensitivity in HL60 Cells Expressing Wild-Type p53

Photochemistry and Photobiology

Volumn 66, Issue 2, 1997, Pages 265-270

  Fisher, Anita M R ^a   Danenberg, Kathleen ^b   Banerjee, Debabrata ^d   Bertino, Joseph R ^d   Danenberg, Peter ^b   Gomer, Charles J ^a,b,c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PORPHYRIN; PROTEIN P53; RADIOSENSITIZING AGENT; TIN ETIOPURPURIN;

ARTICLE; CELL STRAIN HL 60; CELL SURVIVAL; HUMAN; METABOLISM; POLYMERASE CHAIN REACTION; RADIATION DOSE;

CELL SURVIVAL; HL-60 CELLS; HUMANS; POLYMERASE CHAIN REACTION; PORPHYRINS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031196011     PISSN: 00318655     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-1097.1997.tb08653.x     Document Type: Article

References (42)

1. Reynolds, T. (1997) Photodynamic therapy expands its horizons. J. Natl. Cancer Inst. 89, 112-114.
2. Marcus, S. L. and M. H. Dugan (1992) Global status of photodynamic therapy: the registration process for a new therapy. Lasers Surg. Med. 12, 318-324.
3. Fisher, A. M. R., A. L. Murphree and C. J. Gomer (1995) Clinical and preclinical photodynamic therapy. Lasers Surg. Med. 17, 2-31.
4. Jori, G. and J. Spikes (1984) Biochemistry of porphyrins. In Topics in Photomedicine (Edited by K. Smith), pp. 183-318. Plenum Press, New York.
5. Gomer, C. J. (1991) Preclinical examination of first and second generation photosensitizers used in photodynamic therapy. Photochem. Photobiol. 54, 1093-1107.
6. Nelson, J. S., L. H. Liaw and A. Orenstein (1988) Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin and phthaloeyanine. J Natl. Cancer Inst. 80, 1599-1605.
7. Henderson, B. W., S. M. Waldow, T. S. Mang, W. R. Potter, P. B. Malone and T. J. Dougherty (1985) Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res. 45, 572-576.
8. Agarwal, M. L., M. E. Clay, E. J. Harvey, H. H. Evans, A. R. Antunez and N. L. Oleinick (1991) Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res. 51, 5993-5996.
9. Zaidi, S. I. A., N. L. Oleinick, M. T. Zaim and H. Mukhtar (1993) Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice: electron microscopic, histopathologic and biochemical evidence. Photochem. Photobiol. 58, 771-776.
10. Zhou, C., C. Shunji, L. Junlin, G. Jori and C. Milanesi (1996) Apoptosis of mouse ms-2 fibrosarcoma cells induced by photodynamic therapy with Zn (II) phthalocyanine. J. Photochem. Photobiol. B 33, 219-223.
11. Rusch, V., D. Klimstra, E. Venkatrama, J. Oliver, N. Martini, R, Gralla, M. Kris and E. Dmitrovsky (1995) Aberrant p53 expression predicts clinical resistance to cisplatin based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 55, 5038-5042.
12. Harris, C. C. and M. Hollstein (1993) Clinical implications of the p53 tumor suppressor gene. N. Engl. J. Med. 32, 1318-1327.
13. Fisher, D. E. (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78, 539-542.
14. Hollstein, M., D. Sidransky, B. Vogelstein and C. C. Harris (1991) p53 mutations in human cancers. Science 253, 49-53.
15. Lowe, S. W., S. Bodis, A. McClatchey, L. Remington, H. E. Ruley, D. E. Fisher, D. E. Housman and T. Jacks (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810.
16. Goh, H. S., J. Yao and D. R. Smith (1995) p53 mutation and survival in colorectal cancer patients. Cancer Res. 55, 5217-5221.
17. Gallardo, D., K. E. Drazen and W. H. McBride (1996) Adenovirus based transfer of wild type p53 gene increases ovarian tumor radiosensitivity. Cancer Res. 56, 4891-4893.
18. Benhattar, J., J. P. Cerottimi, E. Sarage, G. Metthez and J. C. Givel (1996) p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinoma. Int. J. Cancer 69, 190-192.
19. Aas, T., A. L. Borresen, S. Geisler, B. Smith-Sorensen, H. Johnson, J. A. Varhaug, L. A. Akslen and P. E. Lonning (1996) Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med. 2, 811-814.
20. Iwadate, Y., S. Fujimoto, M. Tagawa, H. Namba, K. Sueyoshi, M. Hirose and S. Sakiyama (1996) Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int. J. Cancer 69, 236-240.
21. Fujiwara, T., E. A. Grimm, T. Mukhopadhyay, W. W. Zhang, L. B. Owen-Schaub and J. A. Roth (1994) Induction of chemosensitivity in human lung cancer cells in-vivo by adenovirus mediated transfer of the wild type p53 gene. Cancer Res. 54, 2287-2291.
22. Hawkins, D. S., G. W. Deniers and D. A. Galloway (1996) Inactivalion of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56, 892-898.
23. Brachman, D. G., M. Beckett, D. Graves, D. Haraf, E. Vokes and R. R. Weichselbaum (1993) p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 53, 3667-3669.
24. Banerjee, D., H.-J. Lenz, B. Schnieders, D. J. Manno, J. F. Ju, C. P. Spears, D. Hochhauser, K. Danenberg, P. Danenberg and J. R. Bertino (1995) Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. Cell Growth Differ. 6, 1405-1413.
25. Luna, M. C. and C. J. Gomer (1991) Isolation and initial characterization of mouse tumor cells resistant to porphyrin mediated photodynamic therapy. Cancer Res. 51, 4243-4249.
26. Gomer, C. J., N. Rucker, A. Banerjee and W. F. Benedict (1983) Comparison of mutagenicity and induction of sister chromatid exchange in Chinese hamster cells exposed to hematoporphyrin derivative photoradiation, ionizing radiation or ultraviolet radiation. Cancer Res. 43, 2622-2627.
27. Gomer, C. J., S. W. Ryter, A. Ferrario, N. Rucker, S. Wong and A. M. R. Fisher (1996) Photodynamic therapy mediated oxidative stress can induce expression of heat shock proteins. Cancer Res. 56, 2335-2360.
28. Chomczynski, P. and N. Sacchi (1987) Single step method of RNA isolation by acid guanidinium thiocyanate phenol chloroform extraction. Anal. Biochem. 162, 156-159.
29. Wolf, D. and V. Rotter (1985) Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc. Natl. Acad. Sci. USA 82, 790-794.
30. Greenblatt, M. S., W. P. Bennett, M. Hollstein and C. C. Harris (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-1878.
31. Miyashita, T., S. Klajewski, M. Klajewshi, H. G. Wang, H. K. Lin, D. A. Liebermann, B. Hoffman and J. C. Reed (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in-vitro and in-vivo. Oncogene 9, 1799-1805.
32. Koechli, O. R., G. N. Schaer, B. Seifert, R. Hornung, U. Haller, U. Eppenberger and H. Mueller (1994) Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344, 1647-1648.
33. Wosikowski, K., J. T. Regis, R. W. Robey, M. Alvarez, J. T. M. Buters, J. M. Gudas and S. E. Bates (1995) Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ. 6, 1395-1403.
34. Ford, J. M. and P. C. Hanawalt (1995) Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription coupled repair and enhanced UV resistance. Proc. Natl. Acad. Sci. USA 92, 8876-8880.
35. Han, Z., D. Chatterjee, D. M. He, J. Early, P. Pantazis, J. H. Wyche and E. A. Hendrickson (1995) Evidence for a G2 check-point in p53-independent apoptosis induction by X-irradiation. Mol. Cell. Biol. 15, 5849-5857.
36. Strasser, A., A. W. Harris, T. Jacks and S. Cory (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53 independent mechanisms inhibitable by bcl-2. Cell 79, 329-339.
37. Matsubara, K., M. Kubota, S. Adachi, K. Kuwakado, H. Hirota, Y. Wakazono, Y. Akiyama and H. Mikawa (1994) Different mode of death induced by calcium ionophore in human leukemia cell lines: possible role of constitutive endonuclease. Exp. Cell Res. 210, 19-25.
38. Agarwal, M. L., H. E. Larkin, S. I. A. Zaidi, H. Mukhtar and N. L. Oleinick (1993) Phospholipase activation triggers apoptosis in photosensitized mouse lymphoma cells. Cancer Res. 53, 5897-5902.
39. Luo, Y. and D. Kessel (1996) The phosphatase inhibitor calyculin antagonizes the rapid initiation of apoptosis by photodynamic therapy. Biochem. Biophys. Res. Commun. 221, 72-76.
40. Yang, E. and S. J. Korsmeyer (1996) Molecular thanatopsis: a discourse on the bcl-2 family and cell death. Blood 88, 386-401.
41. Shimizu, S., Y. Eguchi, W. Kamiike, S. Waguri, Y. Uchiyama, H. Matsuda and Y. Tsujimoto (1996) Retardation of chemical hypoxia induced necrotic cell death by Bcl-2 and ICE inhibitors: possible involvement of common mediators in apoptotic and necrotic signal transductions. Oncogene 11, 2045-2010.
42. He, J., M. L. Agarwal, H. E. Larkin, L. R. Friedman, L. Xue and N. L. Oleinick (1996) The induction of partial resistance to photodynamic therapy by the protooncogene BCL-2. Photochem. Photobiol. 64, 845-852.